← Leaderboards
Francesca T. Aweeka
University Of California San Francisco
$9,163,452
Attributed
$16,361,168
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,361,168 · 10
By mechanism
R01$14,395,432 · 2
P30$1,885,042 · 3
M01$80,694 · 5
Top collaborators
- Sunil Parikh15 shared
- Philip Jon Rosenthal10 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Matthew G Dorsey$21,862,621
- Philip Jon Rosenthal$36,168,903
- Sunil Parikh$7,693,164
- Karen S Hudmon$4,993,521
- Susan J. Fisher$38,160,909
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildDrug KineticsMalariaPharmaceutical PreparationsPregnant WomenPharmacodynamicsUgandaAfricaPharmacologyPregnancyCombined Modality TherapyRegimenDoseAntimalarialsExposure ToArtemisininsResistanceDrug ExposureDrug InteractionsGuidelinesBaseInfectionFundingArtemether
Grant awards (42)
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$656,987
R01 · FY2025 · HD
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$129,641
R01 · FY2025 · HD
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$79,308
R01 · FY2025 · HD
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$930,846
R01 · FY2024 · HD
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$756,520
R01 · FY2024 · AI
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$747,650
R01 · FY2023 · AI
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$731,681
R01 · FY2022 · AI
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$727,306
R01 · FY2021 · AI
Core I: Pharmacology Core$103,599
P30 · FY2021 · AI · contact PI
Optimizing ACT use for African children in the setting of HIV and malnutrition$47,014
R01 · FY2021 · HD · contact PI
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$759,552
R01 · FY2020 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$540,524
R01 · FY2020 · HD · contact PI
Core I: Pharmacology Core$101,895
P30 · FY2020 · AI · contact PI
Pharmacodynamics of Antimalarial Chemoprevention$670,155
R01 · FY2019 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$540,524
R01 · FY2019 · HD · contact PI
Core I: Pharmacology Core$240,676
P30 · FY2019 · AI · contact PI
Pharmacodynamics of Antimalarial Chemoprevention$681,596
R01 · FY2018 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$546,801
R01 · FY2018 · HD · contact PI
Core I: Pharmacology Core$90,676
P30 · FY2018 · AI · contact PI
Pharmacodynamics of Antimalarial Chemoprevention$681,596
R01 · FY2017 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$560,173
R01 · FY2017 · HD · contact PI
Core I: Pharmacology Core$90,673
P30 · FY2017 · AI · contact PI
Pharmacodynamics of Antimalarial Chemoprevention$681,596
R01 · FY2016 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$597,359
R01 · FY2016 · HD · contact PI
Pharmacodynamics of Antimalarial Chemoprevention$700,237
R01 · FY2015 · AI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$503,880
R01 · FY2015 · HD · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$512,768
R01 · FY2014 · HD · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$496,716
R01 · FY2013 · HD · contact PI
Pharmacology$184,202
P30 · FY2013 · AI · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$535,652
R01 · FY2012 · HD · contact PI
Pharmacology$158,792
P30 · FY2012 · AI · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$579,350
R01 · FY2011 · HD · contact PI
Pharmacology Core$181,967
P30 · FY2011 · AI · contact PI
Pharmacology Core$208,389
P30 · FY2010 · AI · contact PI
Pharmacology Core$195,169
P30 · FY2009 · AI · contact PI
Pharmacology Core$159,254
P30 · FY2008 · AI · contact PI
Pharmacology Core$169,750
P30 · FY2007 · AI · contact PI
Effect of ethanol on pharmacokinetics of ARV agents$42,550
M01 · FY2004 · RR
Plasma protein binding and HIV protease inhibitor drug levels$27,821
M01 · FY2004 · RR
Dipyridamole effect on ribavirin pharmacokinetics and tr$9,195
M01 · FY2004 · RR
SCH56592 IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE/PROTEASE INHIBITORS IN HIV$564
M01 · FY2000 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZIDOVUDINE$564
M01 · FY2000 · RR